Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCH 900479 single- and multiple-dose safety, PK, and PD study in healthy postmenopausal women
NL-OMON34172Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SCH 900479 in menopause (3 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability after single oral administration and Safety and tolerability after multiple oral administration. Started Oct 2010; status: active, not recruiting.
02
Drugs
SCH 900479
03
Conditions
menopause
Beyond the preview
Go deeper on NL-OMON34172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34172.